You are here
Motif Bio Announces New Iclaprim Data Presented at ASM Microbe 2018
- Pooled efficacy and safety data from REVIVE Phase 3 trials presented
- Data also published in peer-reviewed journal, International Journal of Antimicrobial Agents
NEW YORK, June 11, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced that the pooled efficacy and safety data from its two Phase 3 trials (REVIVE-1 and REVIVE-2) in patients with acute bacterial skin and skin structure infections (ABSSSI) treated with its investigational drug candidate iclaprim were presented at the American Society of Microbiology (ASM) Microbe 2018 meeting in Atlanta, GA (An Analysis of Pooled Efficacy Data from Two Phase 3 Trials of Iclaprim Compared to Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections, #640 and A Pooled Analysis of Two Phase 3, Randomized, Double-Blind, Multicenter Studies to Evaluate the Safety of Intravenous Iclaprim versus Vancomycin, #641). The pooled data demonstrate that iclaprim was non-inferior to standard-of-care vancomycin and was well tolerated in this patient population. The posters are available on the Motif Bio website here. The pooled data have also been published in the peer-reviewed scientific journal, International Journal of Antimicrobial Agents (https://doi.org/10.1016/j.ijantimicag.2018.05.012).
“ABSSSI is a serious infection for which patients may be hospitalised for several days. Many of these ABSSSI patients have comorbidities, such as renal impairment and diabetes,” said G. Ralph Corey, MD, Vice Chair for Education and Global Health and Gary Hock Professor at Duke University School of Medicine and a principal investigator in the REVIVE-2 trial. “For these patients in particular, there is an urgent need for better treatment options. Iclaprim has a fixed dose, with no dosage adjustment required in patients with renal impairment or in obese patients, and no kidney toxicity was observed in the REVIVE trials. Iclaprim, if approved, may offer advantages over standard of care antibiotics in hospitalised ABSSSI patients, particularly those with renal impairment and/or diabetes.”
Both the REVIVE-1 and REVIVE-2 studies were global Phase 3 trials evaluating iclaprim in patients with ABSSSI. As previously reported, both studies met their primary endpoints of non-inferiority (NI) (10% margin) compared to vancomycin, the current standard of care, at the early timepoint (ETP), 48 to 72 hours after the start of administration of the study drug, in the intent-to-treat (ITT) patient population. The pooled data set included over 1,190 patients.
Iclaprim was well tolerated in the two Phase 3 studies compared to vancomycin. In most patients, adverse events were mild to moderate, with severe adverse events reported in less than 5% of all patients in the pooled data set. The most frequent adverse reactions in both iclaprim and vancomycin-treated patients were headache and nausea. No deaths occurred among patients treated with iclaprim, while three deaths occurred in the vancomycin group.
Acute kidney injury or elevated serum creatinine was reported in seven patients treated with vancomycin, which is known to be nephrotoxic. In contrast, none of the patients treated with iclaprim experienced acute kidney injury or elevated serum creatinine.
For further information please contact:
|Motif Bio email@example.com|
|Graham Lumsden (Chief Executive Officer)|
|Walbrook PR Ltd. (UK FINANCIAL PR & IR)||+44 (0) 20 7933 8780|
|Paul McManus/Helen Cresswell/Lianne Cawthorne|
|MC Services AG (EUROPEAN IR)||+49 (0)89 210 2280|
|Solebury Trout (US IR)||+ 1 (646) 378-2936|
|Russo Partners (US PR)||+1 (858) 717-2310 or +1 (212) 845 4272|
|Travis Kruse, Ph.D.||firstname.lastname@example.org|
Note to Editors:
Iclaprim is a novel investigational antibiotic with a targeted Gram-positive spectrum of activity. In contrast to commonly used broad-spectrum antibiotics, this “precision medicine approach” is consistent with antibiotic stewardship principles which, among other things, seek to reduce the inappropriate use of broad-spectrum products to avoid the build-up of resistance and to lessen the impact on the microbiome of the patient.
Iclaprim has a different and underutilised mechanism of action compared to most other antibiotics. Following positive results from two Phase 3 trials (REVIVE-1 and REVIVE-2), a rolling submission of a New Drug Application (NDA) with the U.S. Food & Drug Administration (FDA) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) has been initiated and is expected to be completed in the second quarter of 2018. To date, iclaprim has been studied in over 1,400 patients and healthy volunteers. Clinical and microbiological data indicate that iclaprim has a targeted Gram-positive spectrum of activity, low propensity for resistance development and favourable tolerability profile. In clinical studies, iclaprim has been administered intravenously at a fixed dose with no dosage adjustment required in patients with renal impairment or in obese patients. The iclaprim fixed dose may, if approved, help reduce the resources required in hospitals since dosage adjustment by health care professionals is avoided and overall hospital treatment costs may be lower, especially in patients with renal impairment. Many standard of care Gram-positive antibiotics are not suitable for hospitalized ABSSSI patients with renal impairment due to efficacy and/or safety issues.
About Motif Bio
Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB) is a clinical-stage biopharmaceutical company focused on developing novel antibiotics for hospitalised patients and designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria, including MRSA. The Company’s lead product candidate is iclaprim. Following positive results from two Phase 3 trials (REVIVE-1 and REVIVE-2), a rolling submission of an NDA with the U.S. FDA for the treatment of acute bacterial skin and skin structure infections (ABSSSI) has been initiated and is expected to be completed in the second quarter of 2018. More than 3.6 million patients with ABSSSI are hospitalised annually in the U.S. It is estimated that up to 26% of hospitalized ABSSSI patients have renal impairment. The Company believes, based on the data from the Phase 3 REVIVE studies, that iclaprim may be suitable for first-line empiric therapy in ABSSSI patients, including those with renal impairment, with or without diabetes.
The Company also plans to develop iclaprim for hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), as there is a high unmet need for new therapies in this indication. A Phase 2 trial in patients with HABP has been successfully completed and a Phase 3 trial is being planned. Additionally, iclaprim has been granted orphan drug designation by the FDA for the treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis and is in preclinical development for this indication.
Iclaprim has received Qualified Infectious Disease Product (QIDP) designation from the FDA together with Fast Track status. Upon acceptance by the FDA of an NDA, iclaprim will receive Priority Review status and, if approved as a New Chemical Entity, will be eligible for 10 years of market exclusivity in the U.S. from the date of first approval, under the Generating Antibiotic Incentives Now Act (the GAIN Act). In Europe, 10 years of market exclusivity is anticipated.
This press release contains forward-looking statements. Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Motif Bio’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Motif Bio believes that these factors include, but are not limited to, (i) the timing, progress and the results of clinical trials for Motif Bio’s product candidates, (ii) the timing, scope or likelihood of regulatory filings and approvals for Motif Bio’s product candidates, (iii) Motif Bio’s ability to successfully commercialise its product candidates, (iv) Motif Bio’s ability to effectively market any product candidates that receive regulatory approval, (v) Motif Bio’s commercialisation, marketing and manufacturing capabilities and strategy, (vi) Motif Bio’s expectation regarding the safety and efficacy of its product candidates, (vii) the potential clinical utility and benefits of Motif Bio’s product candidates, (viii) Motif Bio’s ability to advance its product candidates through various stages of development, especially through pivotal safety and efficacy trials, (ix) Motif Bio’s estimates regarding the potential market opportunity for its product candidates, and (x) the factors discussed in the section entitled “Risk Factors” in Motif Bio’s Annual Report on Form 20-F filed with the SEC on April 10, 2018, which is available on the SEC’s web site, www.sec.gov. Motif Bio undertakes no obligation to update or revise any forward-looking statements.